Back to Results
First PageMeta Content
Health care in the United States / Economy of the Arab League / American Recovery and Reinvestment Act


MANAGEMENT’S DISCUSSION AND ANALYSIS OF RESULTS OF OPERATIONS AND FINANCIAL CONDITION Organization and Business Segments Results of Operations Analysis of Sales by Business Segments Analysis of Consolidated Earnings Be
Add to Reading List

Document Date: 2014-03-06 17:16:31

Open Document

File Size: 134,04 KB

Share Result on Facebook

Company

The Carlyle Group / Synthes Inc. / Gilead Sciences Inc. / Johnson & Johnson / DePuy / McNEILPPC Inc. / Vertex / Ortho-Clinical Diagnostics / Cordis Corporation / Johnson & Johnson Development Corporation / Company’s Pharmaceutical / /

Continent

Europe / /

Country

Germany / Switzerland / Netherlands / Italy / Sweden / Belgium / France / Japan / Austria / United States / Canada / United Kingdom / Luxembourg / Spain / Greece / Denmark / /

Currency

USD / /

Event

FDA Phase / Product Issues / Business Partnership / M&A / Reorganization / /

Facility

Company’s Pharmaceutical pipeline / /

IndustryTerm

joint reconstruction products / biosurgical products / disease products / acquired products / higher margin products / endoscopy products / treatment of patients with mantle cell lymphoma / pelvic floor products / treatment of patients with multicentric Castleman disease / fixed-dose antiretroviral combination product / Diabetes Care / energy products / /

MedicalCondition

Astigmatism / mantle cell lymphoma / previously-untreated multiple myeloma / cirrhosis / compensated liver disease / severely active rheumatoid arthritis / refractory chronic lymphocytic leukemia /small lymphocytic lymphoma / severely active ulcerative colitis / diabetes / multicentric Castleman disease / Infection Prevention/Other / infection / Infectious disease / refractory mantle cell lymphoma / active psoriatic arthritis / chronic hepatitis C / /

MedicalTreatment

chemotherapy / surgery / catheter / drug therapy / /

Organization

European Medicines Agency / U.S. Food and Drug Administration / European Commission / /

Position

general corporate purposes / /

Product

VELCADE / INTELENCE / INVEGA / DURAGESIC / CONCERTA / dexamethasone / RISPERDAL / DOXIL / REMICADE / risperidone / mercaptopurine / EPREX / rabeprazole sodium / BYSTOLIC / PREZISTA / ACIPHEX / ribavirin / doxorubicin hydrochloride / Fentanyl / azathioprine / INVOKANA® (canagliflozin) / SIMPONI® (golimumab) / New Drug / NEVO™ Sirolimus / VELCADE® (bortezomib) / Crucell vaccine / OLYSIO™ (simeprevir) / IMBRUVICA™ / STELARA® (ustekinumab) / anti - rheumatic drug therapy / SIMPONI® ARIATM / response / Crucell / IMBRUVICA™ (ibrutinib) capsules / /

Technology

Neuroscience / transplantation / chemotherapy / genotype / /

SocialTag